Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Carboplatin
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Female
Humans
Idiopathic Interstitial Pneumonias
/ chemically induced
Japan
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Paclitaxel
/ administration & dosage
Pilot Projects
Prospective Studies
Survival Analysis
Treatment Outcome
Acute exacerbation
Chemotherapy
Idiopathic pulmonary fibrosis
Paclitaxel
Re-challenge
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
12
10
2018
accepted:
20
07
2019
pubmed:
29
7
2019
medline:
23
2
2020
entrez:
29
7
2019
Statut:
ppublish
Résumé
Idiopathic interstitial pneumonias (IIPs) are associated with increased risk of lung cancer. In Japan, acute exaberation of IIPs induced by anticancer treatment is a critical issue. For this reason, there is limited available evidence regarding the optimal treatment approach for lung cancer patients complicated with IIPs. Our previous prospective pilot study demonstrated the safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer (NSCLC) with IIPs. The current study was conducted to confirm the results of the same combination therapy used in a larger patient population. Chemotherapy-naïve patients with advanced stage or post-operative recurrent NSCLC patients complicated by IIPs were enrolled. Patients received paclitaxel (100 mg/m Thirty-three of 35 enrolled patients were evaluable for analysis and received a median of four treatment cycles (range 1-6). Four patients (12.1%; 95% confidence interval 3.4-28.2%) had acute exacerbation (AEx)-related IIPs to the study treatment. However, no fatalities due to AEx were observed. The overall response was 69.7%. The median progression-free survival, median survival time, and 1-year survival were 6.3 months, 19.8 months, and 55.4%, respectively. The efficacy of carboplatin plus weekly paclitaxel treatment for advanced NSCLC patients with IIPs was comparable to that of conventional chemotherapy in advanced NSCLC patients without IIPs. Moreover, the primary endpoint was set to the frequency of treatment-related acute exacerbation, and the primary endpoint was met. These results suggest that patients with advanced NSCLC complicated by IIPs may benefit from this combination chemotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Idiopathic interstitial pneumonias (IIPs) are associated with increased risk of lung cancer. In Japan, acute exaberation of IIPs induced by anticancer treatment is a critical issue. For this reason, there is limited available evidence regarding the optimal treatment approach for lung cancer patients complicated with IIPs. Our previous prospective pilot study demonstrated the safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer (NSCLC) with IIPs. The current study was conducted to confirm the results of the same combination therapy used in a larger patient population.
METHODS
METHODS
Chemotherapy-naïve patients with advanced stage or post-operative recurrent NSCLC patients complicated by IIPs were enrolled. Patients received paclitaxel (100 mg/m
RESULTS
RESULTS
Thirty-three of 35 enrolled patients were evaluable for analysis and received a median of four treatment cycles (range 1-6). Four patients (12.1%; 95% confidence interval 3.4-28.2%) had acute exacerbation (AEx)-related IIPs to the study treatment. However, no fatalities due to AEx were observed. The overall response was 69.7%. The median progression-free survival, median survival time, and 1-year survival were 6.3 months, 19.8 months, and 55.4%, respectively.
CONCLUSIONS
CONCLUSIONS
The efficacy of carboplatin plus weekly paclitaxel treatment for advanced NSCLC patients with IIPs was comparable to that of conventional chemotherapy in advanced NSCLC patients without IIPs. Moreover, the primary endpoint was set to the frequency of treatment-related acute exacerbation, and the primary endpoint was met. These results suggest that patients with advanced NSCLC complicated by IIPs may benefit from this combination chemotherapy.
Identifiants
pubmed: 31352631
doi: 10.1007/s10147-019-01516-9
pii: 10.1007/s10147-019-01516-9
doi:
Substances chimiques
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1543-1548Références
Anticancer Res. 2006 Jul-Aug;26(4B):3083-7
pubmed: 16886638
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Surg Oncol. 2001 Jan;76(1):53-7
pubmed: 11223825
AJR Am J Roentgenol. 1997 Jan;168(1):79-83
pubmed: 8976924
Am J Med. 1990 Apr;88(4):396-404
pubmed: 2183601
Am J Respir Crit Care Med. 2005 May 1;171(9):1040-7
pubmed: 15665326
J Thorac Oncol. 2011 Jul;6(7):1242-6
pubmed: 21623239
Chest. 1993 Jun;103(6):1808-12
pubmed: 8404104
Respirology. 2010 Jan;15(1):88-92
pubmed: 19947998
Respirology. 2017 May;22(4):750-757
pubmed: 27997064
Lung Cancer. 2011 Jan;71(1):70-4
pubmed: 20493578
Am J Respir Crit Care Med. 2000 Jan;161(1):5-8
pubmed: 10619790
Intern Med. 2009;48(9):665-72
pubmed: 19420811
Thorax. 1980 Jul;35(7):496-9
pubmed: 7434310
Ann Oncol. 2007 Feb;18(2):317-23
pubmed: 17079694
J Clin Oncol. 2003 Aug 1;21(15):2933-9
pubmed: 12885812
Radiology. 1999 May;211(2):555-60
pubmed: 10228542
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Cancer Chemother Pharmacol. 2015 Jul;76(1):69-74
pubmed: 25976217
Radiology. 1992 Feb;182(2):337-42
pubmed: 1732946
Am J Respir Crit Care Med. 2014 Oct 1;190(7):773-9
pubmed: 25162152
Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304
pubmed: 11790668
Chest. 1999 Nov;116(5):1168-74
pubmed: 10559072
Respir Investig. 2016 Sep;54(5):327-33
pubmed: 27566380
Eur Respir J. 2010 Apr;35(4):821-9
pubmed: 19996196
Eur Respir J. 2001 Jun;17(6):1216-9
pubmed: 11491167